A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

The MAD portion of the study enrolled a total of 76 participants.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The first phase of the Capital ...

Revolution Medicines expects top-line data from the Phase III RASolute 302 trial in second-line PDAC in 1H 2026; the study is designed as an OS event-driven program and is powered primarily for ...

Phase shifters and transmission line technologies are integral components in modern RF and microwave engineering, enabling precise control of signal phase for applications ranging from beamforming in ...

Notes: 1) Efficacy population (n=39), includes all randomized participants who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment. 2) ...

PITTSBURGH — The second phase of the ongoing University Line project is moving forward. Pittsburgh Regional Transit announced on Friday that a $99.8 million construction contract had been awarded to ...

Glenfarne Group, LLC subsidiary Glenfarne Alaska LNG, LLC ("Glenfarne"), majority owner and developer of the Alaska LNG Project, today announced a series of major advances that move Phase One of the ...